CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 276.47 AUD 1% Market Closed
Market Cap: 133.9B AUD
Have any thoughts about
CSL Ltd?
Write Note

Relative Value

The Relative Value of one CSL stock under the Base Case scenario is 286 AUD. Compared to the current market price of 276.47 AUD, CSL Ltd is Undervalued by 3%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSL Relative Value
Base Case
286 AUD
Undervaluation 3%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
54
Median 3Y
8
Median 5Y
8.8
Industry
7.7
Forward
5.5
vs History
98
vs Industry
4
Median 3Y
38.8
Median 5Y
39.7
Industry
22.2
Forward
26.5
vs History
76
vs Industry
5
Median 3Y
33.6
Median 5Y
34.1
Industry
22.3
vs History
42
vs Industry
1
Median 3Y
74
Median 5Y
75.9
Industry
25.5
vs History
95
vs Industry
15
Median 3Y
6
Median 5Y
6.6
Industry
2.5
vs History
96
vs Industry
44
Median 3Y
7.8
Median 5Y
8.8
Industry
7.8
Forward
6.1
vs History
96
vs Industry
29
Median 3Y
14.3
Median 5Y
16.4
Industry
9
vs History
96
vs Industry
5
Median 3Y
23.4
Median 5Y
25.8
Industry
3.9
Forward
17.8
vs History
98
vs Industry
4
Median 3Y
29
Median 5Y
30.6
Industry
3.6
Forward
20.9
vs History
61
vs Industry
4
Median 3Y
35.8
Median 5Y
36.3
Industry
5.2
vs History
74
vs Industry
2
Median 3Y
83
Median 5Y
83.4
Industry
3.3
vs History
93
vs Industry
39
Median 3Y
3.3
Median 5Y
5.9
Industry
4.6

Multiples Across Competitors

CSL Competitors Multiples
CSL Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.4B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 11 -243 24.2 25.5
US
Gilead Sciences Inc
NASDAQ:GILD
112.5B USD 4 892.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD 6 17.7 16.1 17.9
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.8B USD 15.2 -95.6 -227.4 -159.8
P/E Multiple
Earnings Growth
AU
CSL Ltd
ASX:CSL
Average P/E: 208.4
32.9
65%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -243
42%
US
Gilead Sciences Inc
NASDAQ:GILD
892.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -95.6 N/A
EV/EBITDA Multiple
EBITDA Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 17.2
20.3
42%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -227.4 N/A
EV/EBIT Multiple
EBIT Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 22.6
25.3
55%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -159.8 N/A

See Also

Discover More
Back to Top